Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Drugs For Benign Prostatic hypertrophy Market Forecast: What Value Will The Market Reach By 2030?
The market for drugs treating benign prostatic hypertrophy has experienced consistent growth in recent years. It is anticipated to expand from $4.55 billion in 2025 to $4.75 billion in 2026, registering a compound annual growth rate (CAGR) of 4.4%. The historical market expansion is attributable to several factors, including an aging population’s growth, the continued use of alpha blockers, the provision of hospital-based urology care, the wider availability of oral therapies, and advancements in diagnostic tools.
The market for drugs treating benign prostatic hypertrophy is projected to experience robust expansion over the coming years. Its valuation is set to reach $5.83 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. This anticipated growth during the forecast period is primarily driven by factors such as an increase in male life expectancy, improved access to healthcare, advancements in combination drug therapies, the proliferation of outpatient urology clinics, and prevalent lifestyle-related risk factors. Key trends characterizing this period encompass a heightened demand stemming from the aging male demographic, greater uptake of combination therapies, the emergence of minimally invasive drug treatments, the broadening availability of generic BPH drugs, and enhanced awareness leading to earlier diagnoses.
Get A Free Sample Report With In-Depth Market Insights:
Drugs For Benign Prostatic hypertrophy Market Growth Drivers: What’s Behind The Acceleration?
The rising incidence of prostate conditions is anticipated to fuel the expansion of the drugs for benign prostatic hypertrophy market. Prostate diseases are a collection of medical ailments impacting the prostate gland, a male reproductive organ situated just beneath the bladder. This increase in prevalence is largely linked to aging, alongside metabolic and inflammatory elements that foster conditions such as benign prostatic hyperplasia (BPH) and prostate cancer. Medications for benign prostatic hypertrophy (BPH) play a crucial role in managing and easing urinary issues tied to prostate conditions, offering relief through reduced prostate gland size and enhanced urine flow. For instance, in August 2024, Cancer Therapy Advisor, a US-based medical information provider, projected approximately 299,010 new prostate cancer diagnoses in the US in 2024, representing 14.9 percent of all new cancer cases, with over 35,000 projected deaths. Consequently, the heightened occurrence of prostate diseases is stimulating growth in the drugs for benign prostatic hypertrophy market.
Drugs For Benign Prostatic hypertrophy Market Segment Landscape And Growth Outlook
The drugs for benign prostatic hypertrophy market covered in this report is segmented –
1) By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users
Subsegments:
1) By Alpha Blocker: Tamsulosin, Alfuzosin, Doxazosin, Terazosin, Silodosin
2) By 5-alpha Reductase Inhibitor: Finasteride, Dutasteride
3) By Phosphodiesterase-5 Inhibitor: Tadalafil, Sildenafil
4) By Other Types: Anticholinergics, Herbal Supplements (Saw Palmetto), Combination Therapy Drugs (Alpha Blocker + 5-alpha Reductase Inhibitor)
Drugs For Benign Prostatic hypertrophy Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies within the drugs for benign prostatic hypertrophy market are concentrating on developing technologically advanced solutions, such as new medications for both enlarged prostate (benign prostatic hyperplasia, BPH) and erectile dysfunction, to gain a competitive edge. Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland, while erectile dysfunction (ED) refers to the inability to achieve or maintain an erection sufficient for sexual activity. For instance, in September 2023, Akums Drugs and Pharmaceuticals Ltd., an Indian-based paint and coating manufacturing pharmaceutical contract manufacturer, launched Tamsulosin + Tadalafil Capsule. This initiative aimed to expand its product offerings in the pharmaceutical sector, specifically addressing common men’s health issues. This innovative product, Cromax, boasts unique features like a dual-action formulation that combines Tamsulosin, which targets smooth muscle relaxation in the prostate and urethra to improve urine flow, and Tadalafil, which enhances blood flow to the penis to facilitate erections. This combination therapy not only offers a more convenient treatment option for men experiencing both benign prostatic hyperplasia (BPH) and erectile dysfunction but also exhibits significant improvements in the International Prostate Symptom Score (IPSS).
Drugs For Benign Prostatic hypertrophy Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the drugs for benign prostatic hypertrophy market are Astellas Pharma Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Sanofi S.A., Pfizer Inc., Ipsen S.A., Novartis International AG, Bayer AG, Merck & Co. Inc., Endo Pharmaceuticals Inc., Impax Laboratories Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Eli Lilly and Company, Bausch Health Companies Inc., Aurobindo Pharma Limited, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Cipla Ltd
View The Full Drugs For Benign Prostatic hypertrophy Market Report:
Drugs For Benign Prostatic hypertrophy Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the drugs for benign prostatic hypertrophy market in 2025. Middle East is expected to be the fastest-growing region in the drugs for benign prostatic hypertrophy market. The regions covered in the drugs for benign prostatic hypertrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
